tiprankstipranks
Molecular Partners AG (CH:MOLN)
:MOLN
Switzerland Market
MOLN
Molecular Partners AG
RESEARCH TOOLSreports
Want to see CH:MOLN full AI Analyst Report?

Molecular Partners AG (MOLN) Stock News & Sentiment

0 Followers
Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
Premium
Ratings
Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
18d ago
MOLN
Molecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged
Premium
Ratings
Molecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged
2M ago
MOLN
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
Premium
Ratings
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
4M ago
MOLN
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
Premium
Ratings
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
5M ago
MOLN
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
Premium
Ratings
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
6M ago
MOLN
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
Premium
Ratings
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
6M ago
MOLN
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
Premium
Ratings
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
6M ago
MOLN
More CH:MOLN News >

MOLN News on the Web

Clear Street transfers coverage on Molecular Partners, keeps Buy rating
TipRanks News
Bullish
Molecular Partners, Orano Med doses first patient in MP0712 study
TipRanks News
Bullish
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
TipRanks News
Neutral
Molecular Partners AG at TD Cowen Oncology Innovation Summit (Virtual) Transcript
GuruFocus News
Neutral
Molecular Partners announces presentation of preclinical data at AACR
TipRanks News
Bullish
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
TipRanks News
Bullish
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
TipRanks News
Bullish
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0.5 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:MOLN’s Media Buzz Sentiment?
Currently, no data Available
What is CH:MOLN’s weekly average amount of articles?
In an average week, 0.5 articles about CH:MOLN are published.
    What is CH:MOLN’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    KURAKura Oncology
    AXGNAxoGen
    IRONDisc Medicine
    XERSXeris Pharmaceuticals
    LFSTLifestance Health Group
    Showing the stocks with the most bullish news sentiment over the past week